Marrone Bio Innovations Stock Forecast, Price & News

Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions

Is Marrone Bio Innovations a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Marrone Bio Innovations stock.
View analyst ratings for Marrone Bio Innovations or view top-rated stocks.

What stocks does MarketBeat like better than Marrone Bio Innovations?

Wall Street analysts have given Marrone Bio Innovations a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Marrone Bio Innovations wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Marrone Bio Innovations?

Marrone Bio Innovations saw a decline in short interest in September. As of September 30th, there was short interest totaling 1,620,000 shares, a decline of 20.2% from the September 15th total of 2,030,000 shares. Based on an average daily volume of 686,500 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.7% of the company's shares are sold short.
View Marrone Bio Innovations' Short Interest.

When is Marrone Bio Innovations' next earnings date?

Marrone Bio Innovations is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Marrone Bio Innovations.

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations, Inc. (NASDAQ:MBII) released its quarterly earnings results on Sunday, August, 15th. The basic materials company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. The basic materials company had revenue of $12.60 million for the quarter, compared to analysts' expectations of $17.59 million. Marrone Bio Innovations had a negative trailing twelve-month return on equity of 53.18% and a negative net margin of 41.23%.
View Marrone Bio Innovations' earnings history.

How has Marrone Bio Innovations' stock been impacted by Coronavirus (COVID-19)?

Marrone Bio Innovations' stock was trading at $0.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MBII shares have increased by 5.1% and is now trading at $0.9040.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MBII?

5 equities research analysts have issued 12 month target prices for Marrone Bio Innovations' stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Marrone Bio Innovations' stock price to reach $2.90 in the next year. This suggests a possible upside of 220.8% from the stock's current price.
View analysts' price targets for Marrone Bio Innovations or view top-rated stocks among Wall Street analysts.

Who are Marrone Bio Innovations' key executives?

Marrone Bio Innovations' management team includes the following people:

• Kevin R. Helash, Chief Executive Officer & Director
• Sue Cheung, Chief Financial Officer
• Amit Vasavada, Chief Technology Officer, Senior VP-R&D
• Linda V. Moore, Secretary, Chief Compliance Officer & EVP
• Keith J. Pitts, Chief Sustainability Officer & Senior VP

Who are some of Marrone Bio Innovations' key competitors?

Some companies that are related to Marrone Bio Innovations include Bioceres Crop Solutions (BIOX), American Vanguard (AVD), AgroFresh Solutions (AGFS), Calyxt (CLXT), Wynnstay Group (WYN), China Green Agriculture (CGA), Evogene (EVGN), Bion Environmental Technologies (BNET), Eden Research (EDEN), SenesTech (SNES), Save Foods (SVFD), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT), China Agri-Business (CHBU) and Igene Biotechnology (IGNE).
View all of MBII's competitors.

What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Ekso Bionics (EKSO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Enerplus (ERF), ADMA Biologics (ADMA), Great Panther Mining (GPL), OrganiGram (OGI), 22nd Century Group (XXII) and Aeterna Zentaris (AEZS).

What is Marrone Bio Innovations' stock symbol?

Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."

How do I buy shares of Marrone Bio Innovations?

Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marrone Bio Innovations' stock price today?

One share of MBII stock can currently be purchased for approximately $0.90.

How much money does Marrone Bio Innovations make?

Marrone Bio Innovations has a market capitalization of $159.36 million and generates $38.37 million in revenue each year. The basic materials company earns $-20.17 million in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Marrone Bio Innovations have?

Marrone Bio Innovations employs 145 workers across the globe.

What is Marrone Bio Innovations' official website?

The official website for Marrone Bio Innovations is www.marronebioinnovations.com.

Where are Marrone Bio Innovations' headquarters?

Marrone Bio Innovations is headquartered at 1540 Drew Avenue, Davis CA, 95618.

How can I contact Marrone Bio Innovations?

Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at (530) 750-2800 or via email at [email protected].